A liver-tumor adhesion peptide from random phage display library
- 51 Downloads
To identify and localize the synthesized targeting peptide A54 to liver cancer cell line BEL-7502 in vivo and in vitro for confirming the potential clinical application of peptide A54 in hepatocarcinoma targeting therapy.
Phage A54 was confirmed by ELISA. Biotin and FAM labeled A54 peptides were identified and localized by means of immunohistochemistry and immunocytochemistry.
A54 peptide could target the liver-tumor tissue in vivo and adhere to several liver-tumor cells in vitro. FAM-labeled A54 peptides were localized on the membrane surface of liver-tumor cells.
Synthesized A54 peptide obtained from in vivo phage display technology still kept special ability to adhere liver-tumor cell in vivo and in vitro. The A54 peptide could be a candidate carrier for hepatocarcinoma targeting therapy.
Key wordsA54 peptide Identification localization Medicine carrier
Unable to display preview. Download preview PDF.
- Tang ZY. Practical Oncology (Shi-Yong-Zhong-Liu-Xue) [M]. 2ed. Shanghai: Fudan University Press, 2003; p534–535.Google Scholar
- Du Bing, Yu J, Zhou ZL, et al. Selection of the peptides specifically binding to hepatoma by using phage display in vivo[J]. Chin J Oncol 2005; 27: 645–647.Google Scholar